Xeris Biopharma (XERS) Earnings Date, Estimates & Call Transcripts $4.86 -0.22 (-4.23%) As of 01:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Xeris Biopharma Earnings Summary Xeris Biopharma announced Q1 2025 earnings on May 8, 2025, reporting an EPS of -$0.06, which beat analysts' consensus estimates of -$0.07 by $0.01. Quarterly revenue was reported to be $57.80 million, above the consensus estimate of $57.61 million. With a trailing EPS of -$0.30, Xeris Biopharma's earnings are expected to grow next year, from ($0.41) to ($0.22) per share. Latest Q1 Earnings DateMay. 8EstimatedConsensus EPS (May. 8) -$0.07 Actual EPS (May. 8) -$0.06 Beat By $0.01 Actual Revenue (May. 8) $57.80MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Xeris Biopharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xeris Biopharma and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataXERS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.XERS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Xeris Biopharma Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251-$0.08-$0.08-$0.08Q2 20252-$0.06-$0.01-$0.04Q3 20252-$0.01$0.03$0.01Q4 20252$0.01$0.04$0.03 Xeris Biopharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025-$0.07-$0.06+$0.01-$0.06$57.61M$57.80M8/8/2024Q2 2024-$0.11-$0.10+$0.01-$0.10$46.80M$48.07M5/9/2024Q1 2024-$0.12-$0.14 -$0.02-$0.14$41.56M$40.64M3/6/2024Q4 2023-$0.09-$0.10 -$0.01-$0.10$45.50M$44.39M11/9/2023Q3 2023-$0.12-$0.09+$0.03-$0.09$40.93M$48.32M8/8/2023Q2 2023-$0.13-$0.14 -$0.01-$0.14$34.84M$38.01M Xeris Biopharma Earnings - Frequently Asked Questions When did Xeris Biopharma announce their last quarterly earnings? Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earning data on Thursday, May 8, 2025. Learn more on XERS's earnings history. What guidance has Xeris Biopharma issued on next quarter's earnings? Xeris Biopharma issued an update on its FY 2025 earnings guidance on Thursday, May, 8th. The company issued revenue guidance of $260.0 million-$275.0 million, compared to the consensus revenue estimate of $262.3 million. Did Xeris Biopharma beat their earnings estimates last quarter? In the previous quarter, Xeris Biopharma (NASDAQ:XERS) reported ($0.06) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.07) by $0.01. Learn more on analysts' earnings estimate vs. XERS's actual earnings. How can I listen to Xeris Biopharma's earnings conference call? The conference call for Xeris Biopharma's latest earnings report can be listened to online. Listen to Conference Call How can I read Xeris Biopharma's conference call transcript? The conference call transcript for Xeris Biopharma's latest earnings report can be read online. Read Transcript How much revenue does Xeris Biopharma generate each year? Xeris Biopharma (NASDAQ:XERS) has a recorded annual revenue of $222.55 million. How much profit does Xeris Biopharma generate each year? Xeris Biopharma (NASDAQ:XERS) has a recorded net income of -$62.26 million. XERS has generated -$0.30 earnings per share over the last four quarters. What is Xeris Biopharma's EPS forecast for next year? Xeris Biopharma's earnings are expected to grow from ($0.41) per share to ($0.22) per share in the next year. More Earnings Resources from MarketBeat Related Companies MTSR Earnings AKRO Earnings ALVO Earnings CPRX Earnings CRNX Earnings SRRK Earnings MRUS Earnings PTGX Earnings MLTX Earnings IMVT Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds This page (NASDAQ:XERS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XERS Stock Free XERS Stock Alerts